|
MC-MSC.1 |
Phase III |
Behandlung der steroidrefraktären akuten Graft-versus-Host-Krankheit mit mesenchymalen Stromazellen im Vergleich zur besten verfügbaren Therapie (IDUNN) |
|
AlloRelapseMM |
Phase III |
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma subsequent a first-line therapy |
|
PKRPC001 / POA 20201 |
Phase IIIb |
A prospective randomized, double-blind, placebo-controlled, multi-center phase III study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT) |
|
FLAMSACLAX |
Phase III |
Phase-I/II trial to assess the safety and efficacy of Venetoclax in addition to sequential conditioning with Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for allogeneic blood stem cell transplantation in patients with MDS, CMML or sAM |
|
EQUATOR |
Phase III |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease |
|
INCA 34176-254 |
Phase II |
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Eudract Nr. 2022-502168-19-00 |
Menü
